NuCana plc ADR(NCNA) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
September 29 at 4:00 AM ET (Korea 9/29 17:00)
Full metrics table
| Index | - | P/E | - | EPS (ttm) | -3.22 | Insider Own | 6.99% | Shs Outstand | 4.3M | Perf Week | -2.27% |
| Market Cap | 0.01B | Forward P/E | - | EPS next Y | - | Insider Trans | - | Shs Float | 4.0M | Perf Month | -12.24% |
| Enterprise Value | -0.02B | PEG | - | EPS next Q | - | Inst Own | 2.57% | Short Float | 2.67% | Perf Quarter | -18.35% |
| Income | -0.01B | P/S | - | EPS this Y | - | Inst Trans | 1.28% | Short Ratio | 1.77 | Perf Half Y | -7.86% |
| Sales | 0.00B | P/B | 34.41 | EPS next 5Y | - | ROA | -46.15% | Short Interest | 0.11M | Perf YTD | -64.17% |
| Book/sh | 0.04 | P/C | 0.21 | EPS past 3/5Y | 83.42% 68.08% | ROE | -70.39% | 52W High | -82.13% ($7.22) | Perf Year | -67.83% |
| Cash/sh | 6.01 | P/FCF | - | Sales past 3/5Y | - | ROIC | -46.96% | 52W Low | 6.61% ($1.21) | Perf 3Y | -99.96% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | 99.5% | Gross Margin | - | Volatility(W/M) | 7.13% 6.67% | Perf 5Y | -99.99% |
| Dividend TTM | - | EV/Sales | - | Sales Y/Y TTM | - | Oper. Margin | - | ATR (14) | 0.09 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 4.73 | EPS Q/Q | 96.76% | Profit Margin | - | RSI (14) | 41.21 | Recom | 3 |
| Dividend Gr. 3/5Y | - | Current Ratio | 4.73 | Sales Q/Q | - | SMA20 | -4.23% ($1.35) | Beta | 2.32 | Target Price | $4750.48 |
| Payout | - | Debt/Eq | 0.03 | Earnings | 2026/8/13 | SMA50 | -7.22% ($1.39) | Rel Volume | 0.39 | Prev Close | $1.28 |
| Employees | 12 | LT Debt/Eq | 0.03 | EPS/Sales Surpr. | - | SMA200 | -37.07% ($2.05) | Avg Volume(3M) | 0.06M | Price | $1.29 |
| IPO | 2017/9/28 | Option/Short | No/Yes | Trades | 191 | Volume | 23,674 | Change | 0.78% |
💊 Nucana (formerly known as NuCana) is a UK-based, Edinburgh-headquartered clinical-stage biopharmaceutical company developing next-generation anticancer drugs by applying its proprietary ProTide technology to widely used nucleoside analog (anticancer) agents, with the goal of improving their efficacy and safety. Its lead assets are NUC-7738, which works via a novel mechanism of action inhibiting RNA polyadenylation and is being evaluated (including in combination therapy) in a Phase 1/2 trial for PD-1-resistant melanoma, and NUC-3373, a next-generation modification of 5-fluorouracil (5-FU).
Over the past 1 year, on the lower side
82% below its 1-year high.
Traded less than usual That is 39% of its average volume.
NCNA has a sound balance sheet but weak earning power
Losses or thin margins. Early-stage growth or weakening competitiveness
Tap to view numbers
It has beaten expectations every time
Beat market estimates in the last 4 quarters.
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -100.0%. The S&P 500 did +77% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Institutions barely hold it
Institutions hold 2.6%.
Tap to view numbers
It ranks #548 of 592 in the industry
Based on market cap of $6M.
FAQ
What kind of company is NCNA?
NCNA belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of NCNA?
The market cap of NCNA is approximately $6M, ranking 5,666 within its sector.
What is the 52-week high and low for NCNA?
NCNA has recorded a 52-week high of $7.22 and a low of $1.21.
